– Follows US FDA new drug application submission in September 2026, marking important global regulatory progress – – Filings supported by positive SAFFRON global Phase III data demonstrating statistically significant and clinically meaningful PFS and OS improvements — Data selected for ESMO 2026 Presidential Symposium and simultaneously published in The New England Journal of Medicine – HONG KONG and FLORHAM PARK, N.J., Nov. 01, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited ("HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that regulatory filings for ORPATHYS® (savolitinib) in combination with TAGRISSO® (osimertinib) have been accepted for review in Europe and Japan.In Europe, the European…